|
Conference/Events
| ShowHide Related Items >><< - 05/25/23
- Oncolytics reports positive response data in Phase 2 breast cancer trial
- 12/08/22
- Oncolytics' Chinese partner presents interim data on breast cancer candidate
- 05/25/23
- I-Mab announces results from CD73 antibody combination study
- 04/25/23
- Tracon announces $23M arbitration award in dispute with I-Mab
- 04/25/23
- I-Mab receives arbitration award relating to Tracon CD73 antibody pact
- 04/24/23
- I-Mab doses first patient in Phase 3 study of lemzoparlimab in MDS in China
- 05/25/23
- Takeda, Hutchmed say Fruquintinib NDA granted priority review by FDA
- 04/17/23
- Hutchmed announces NDA acceptance for Fruquintinib in China
- 04/04/23
- Hutchmed initiates registration phase of HMPL-453 trial
- 03/14/23
- Hutchmed announces closing of fruquintinib license to Takeda
- 05/25/23
- PDS Biotechnology announces 'promising' interim data from VERSATILE-002 trial
- 05/18/23
- PDS Biotechnology completes enrollment in VERSATILE-002 Phase 2 trial
- 05/15/23
- PDS Biotechnology expects cash to fund programs into 3Q24
- 04/27/23
- PDS Biotechnology to present updated data from VERSATILE-002 study
EFTR eFfector Therapeutics - 05/25/23
- eFfector Therapeutics' zotatifin shows positive Phase 2 breast cancer results
- 04/11/23
- eFfector Therapeutics to collaborate with Standford Medicine
- 02/21/23
- eFfector announces top-line results from Phase 1b trial of zotatifin
- 01/05/23
- eFfector Therapeutics provides clinical data update for Zotatifin
- 05/25/23
- Aravive to present 'promising' update from phase 2 trial of Batiraxcept at ASCO
- 05/16/23
- Aravive announces Phase 3 trial design for batiraxcept
- 05/08/23
- Aravive to host virtual KOL event on batiraxcept
- 04/26/23
- Aravive announces poster presentation at ASCO
- 05/31/23
- Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis
- 05/25/23
- Legend: Type II variation application submitted to EMA for CARVYKTI
- 05/25/23
- Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications
- 05/12/23
- Protagonist and Janssen report data from preclinical studies of JNJ-2113
- 05/30/23
- Bristol-Myers' repotrectinib application in lung cancer accepted by FDA
- 05/26/23
- Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination
- 05/25/23
- Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl
- 05/25/23
- Bristol-Myers says Breyanzi first and only CAR-T to deliver efficacy in CLL/SLL
- $740.00 /
+8.995 (+1.23%) - 05/25/23
- Regeneron says updated Linvoseltamab data demonstrates durable responses
- 05/25/23
- Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial
- 05/21/23
- Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results
- 05/18/23
- Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims
- 05/26/23
- Gilead announces CHMP reccomendation for the use of Veklury
- 05/17/23
- Gilead to present advances across its oncology pipeline at ASCO Annual Meeting
- 05/15/23
- Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead
- 05/15/23
- Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus
- 08:11 Today
- Novartis says Kisqali reduced risk of breast cancer recurrence by 25% in study
- 06/01/23
- Pharming to sell PRV to Novartis for $21.1M
- 05/25/23
- EMA accepts Sandoz marketing authorization applications for biosimilar denosumab
- 05/22/23
- Avrobio to sell HSC gene therapy program to Novartis for $87.5M in cash
- 05/18/23
- Mustang Bio announces strategic manufacturing partnership, portfolio updates
- 04/03/23
- Mustang Bio announces 15-for-1 reverse stock split
- 12/19/22
- Mustang Bio provides CAR T cell therapy portfolio updates
- 05/23/23 JonesResearch
- Oncolytics initiated with a Buy at JonesResearch
- 05/23/23 JonesResearch
- Oncolytics initiated with a Buy at JonesResearch
- 03/06/23 Canaccord
- Oncolytics price target lowered to $5.00 from $6.00 at Canaccord
- 03/06/23 Cantor Fitzgerald
- Oncolytics initiated with an Overweight at Cantor Fitzgerald
- 04/03/23 Piper Sandler
- I-Mab price target lowered to $25 from $30 at Piper Sandler
- 04/03/23 H.C. Wainwright
- I-Mab price target lowered to $25 from $45 at H.C. Wainwright
- 08/31/22 H.C. Wainwright
- I-Mab price target lowered to $45 from $70 at H.C. Wainwright
- 08/30/22 Piper Sandler
- I-Mab price target lowered to $30 from $35 at Piper Sandler
- 02/27/23 H.C. Wainwright
- H.C. Wainwright reiterates Buy on PDS following positive FDA meeting
- 01/03/23 H.C. Wainwright
- PDS Biotechnology price target raised to $21 from $15 at H.C. Wainwright
- 12/28/22 B. Riley
- PDS Biotechnology price target raised to $12 from $10 at B. Riley
- 11/14/22 Chardan
- PDS Biotechnology price target raised to $16 from $15 at Chardan
EFTR eFfector Therapeutics - 05/26/23 Mizuho
- eFfector Therapeutics posted positive breast cancer data, says Mizuho
- 05/26/23 Stifel
- eFfector Therapeutics upgraded to Buy from Hold at Stifel
- 03/15/23 H.C. Wainwright
- Aravive price target raised to $12 from $7 at H.C. Wainwright
- 01/04/23 EF Hutton
- Aravive initiated with a Buy at EF Hutton
- 11/13/22 Piper Sandler
- Aravive price target lowered to $2 from $6 at Piper Sandler
- 10/27/22 Roth Capital
- Aravive price target lowered to $10 from $15 at Roth Capital
- 05/30/23 RBC Capital
- Kenvue initiated with an Outperform at RBC Capital
- 05/30/23 Citi
- Johnson & Johnson resumed with a Buy at Citi
- 05/30/23 JPMorgan
- JPMorgan starts Kenvue with Overweight on 'resilient growth'
- 05/30/23 Goldman Sachs
- Kenvue initiated with a Neutral at Goldman Sachs
- 05/01/23 Barclays
- Bristol-Myers price target lowered to $65 from $66 at Barclays
- 04/28/23 Credit Suisse
- Bristol-Myers price target lowered to $72 from $78 at Credit Suisse
- 04/21/23 BofA
- Bristol-Myers price target raised to $85 from $82 at BofA
- 04/20/23 H.C. Wainwright
- Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
- $740.00 /
+8.995 (+1.23%) - 05/19/23 Piper Sandler
- Regeneron Q1 Eylea miss 'not about share, says Piper Sandler
- 05/08/23 Guggenheim
- Regeneron price target lowered to $935 from $960 at Guggenheim
- 05/05/23 Morgan Stanley
- Regeneron price target raised to $927 from $880 at Morgan Stanley
- 05/05/23 SVB Securities
- Regeneron price target lowered to $895 from $976 at SVB Securities
- 08:25 Today Argus
- Gilead continues to make regulatory progress, says Argus
- 05/16/23 BMO Capital
- Gilead upgraded to Outperform from Market Perform at BMO Capital
- 04/28/23 Piper Sandler
- Gilead assumed with an Overweight at Piper Sandler
- 04/12/23 Morgan Stanley
- Gilead price target raised to $85 from $81 at Morgan Stanley
- 05/19/23 JPMorgan
- JPMorgan places 'Negative Catalyst Watch' on Novartis into data
- 04/26/23 Barclays
- Novartis price target raised to CHF 90 from CHF 85 at Barclays
- 04/26/23 Credit Suisse
- Novartis price target raised to CHF 90 from CHF 80 at Credit Suisse
- 04/26/23 JPMorgan
- Novartis price target raised to CHF 92 from CHF 85 at JPMorgan
- 05/26/23 B. Riley
- Mustang Bio price target raised to $10 from $4 at B. Riley
- 11/16/22 BTIG
- Mustang Bio price target lowered to $4 from $8 at BTIG
- 08/17/22 BTIG
- Bluebird's approval has positive read for Mustang Bio, says BTIG
- 07/14/22 B. Riley
- Mustang Bio price target lowered to $4 from $5 at B. Riley
- 03/03/23
- Oncolytics reports Q4 EPS (C$0.14) vs. (C$0.14) last year
- 05/15/23
- PDS Biotechnology reports Q1 EPS (32c), consensus (31c)
- 03/28/23
- PDS Biotechnology reports 2022 EPS ($1.43), consensus ($1.08)
EFTR eFfector Therapeutics - 05/09/23
- eFfector Therapeutics reports Q1 EPS (24c), consensus (14c)
- 03/08/23
- eFfector Therapeutics reports Q4 EPS (22c), consensus (24c)
- 05/10/23
- Aravive reports Q1 EPS (66c), consensus (32c)
- 03/15/23
- Aravive reports Q4 EPS (46c), consensus (30c)
- 04/18/23
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65
- 04/18/23
- Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51
- 04/17/23
- Notable companies reporting before tomorrow's open
- 02/28/23
- Fate Therapeutics reports Q4 EPS (58c), consensus (86c)
- 04/27/23
- Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06
- 04/27/23
- Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97
- 04/26/23
- Notable companies reporting before tomorrow's open
- 04/26/23
- Notable companies reporting before tomorrow's open
- $740.00 /
+8.995 (+1.23%) - 05/04/23
- Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56
- 02/03/23
- Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03
- 02/02/23
- Notable companies reporting before tomorrow's open
- 02/02/23
- Notable companies reporting before tomorrow's open
- 05/15/23
- Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c
- 04/27/23
- Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84
- 04/27/23
- Gilead reports Q1 Biktarvy sales up 24% y/y
- 04/27/23
- Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54
- 04/25/23
- Novartis reports Q1 EPS $1.71, consensus $1.55
- 02/01/23
- Novartis sees core operating income to grow mid single digit percentage in 2023
- 02/01/23
- Novartis reports Q4 core EPS $1.52, consensus $1.44
- 05/12/23
- Mustang Bio reports Q1 EPS ($2.06) vs. ($2.71) last year
- 05/26/23
- Health authorities to target next COVID shot to new strain, WSJ says
- 05/23/23
- Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports
- 05/10/23
- New suitors showing interest in ShockWave Medical, Street Insider says
- 05/03/23
- Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says
- 01/04/23
- Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says
- $740.00 /
+8.995 (+1.23%) - 05/17/23
- Regeneron CEO backs regulators attempt to block Amgen deal, FT reports
- 04/14/23
- FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron's says
- 03/22/23
- Novartis halts Leqvio heart attack prevention trial, Reuters reports
- 02/08/23
- Avrobio exploring potential sale after approach, Street Insider says
- 12/29/22
- Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports
- 05/25/23
- Fly Intel: After-Hours Movers
- 05/25/23
- Fly Intel: After-Hours Movers
- 01/03/23
- What You Missed On Wall Street On Tuesday
- 01/03/23
- What You Missed On Wall Street This Morning
EFTR eFfector Therapeutics - 05/26/23
- What You Missed On Wall Street On Friday
- 05/26/23
- What You Missed On Wall Street This Morning
- 15:50 Today
- Buy/Sell: Wall Street's top 10 stock calls this week
- 05/30/23
- What You Missed On Wall Street On Tuesday
- 05/30/23
- What You Missed On Wall Street This Morning
- 05/30/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/06/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/02/23
- Fly Intel: Pre-market Movers
- 01/17/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $740.00 /
+8.995 (+1.23%) - 03/28/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/27/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/24/23
- What You Missed On Wall Street On Friday
- 03/24/23
- What You Missed On Wall Street This Morning
- 05/16/23
- What You Missed On Wall Street On Tuesday
- 05/16/23
- What You Missed On Wall Street This Morning
- 05/16/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/28/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/24/23
- Biotech Alert: Searches spiking for these stocks today
- 05/22/23
- Fly Intel: Pre-market Movers
- 03/22/23
- What You Missed On Wall Street On Wednesday
- 03/22/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Largest borrow rate increases among liquid names
- 04/18/23
- Unusually active option classes on open April 18th
- 04/06/23
- Unusually active option classes on open April 6th
- 04/05/23
- Early notable gainers among liquid option names on April 5th
- 04/05/23
- Unusually active option classes on open April 5th
- 03/10/23
- Bristol Myers Squibb put volume heavy and directionally bearish
- 02/24/23
- Bristol Myers Squibb put volume heavy and directionally bearish
- $740.00 /
+8.995 (+1.23%) - 03/23/23
- Early notable gainers among liquid option names on March 23rd
- 05/25/23
- Gilead call volume above normal and directionally bullish
- 05/03/23
- Gilead call volume above normal and directionally bullish
- 04/27/23
- Gilead options imply 3.8% move in share price post-earnings
- 02/03/23
- Early notable gainers among liquid option names on February 3rd
- 01/09/23
- Novartis call volume above normal and directionally bullish
- 12/16/22
- Novartis call volume above normal and directionally bullish
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 06/01/23
- Dollar General falls -19.8%
- 06/01/23
- Dollar General continuing to see signs of financial strain on customers
- 06/01/23
- Dollar General has seen positive comp sales through first 3 weeks of Q2
- 06/01/23
- Dollar General falls -16.3%
- $13.45 /
-7.285 (-35.13%) - 12:00 Today
- SentinelOne falls -36.6%
- 10:00 Today
- SentinelOne falls -31.9%
- 09:47 Today
- SentinelOne falls -35.1%
- 06/01/23
- SentinelOne down 32% at $14.01 per share after Q1 results, guidance cut
- 06/01/23
- Boeing awarded $200M Navy contract modification
- 06/01/23
- Airbus gets order for seven wide-body aircraft from Air Algerie
- 05/25/23
- Boeing CFO: Parts of supply chain not where they need to be
- 05/25/23
- Boeing CFO: Demand environment 'favorable'
- 06/01/23
- Par Pacific completes acquisition of Exxon Mobil Billings refinery
- 06/01/23
- Nucor enters into carbon capture and storage agreement with Exxon Mobil
- 05/22/23
- Chord Energy to acquire assets in the Williston Basin for $375M
- 05/02/23
- TechnipFMC awarded large subsea contract for ExxonMobil Guyana's Uaru project
- 05/22/23
- Chevron to acquire PDC Energy in $6.3B all-stock transaction
- 05/15/23
- Berkshire Hathaway takes stake in Capital One, exits RH
- 05/15/23
- Tiger Management adds Nvidia in Q1, sells out of Toast and Chevron
- 04/28/23
- Chevron expects to repurchase $4.375B in shares in Q2
- 06/01/23
- Nvidia CFO Kress sells $2.5M in company shares
- 05/31/23
- Cathie Wood's ARK Investment sold 23.3M shares of Nvidia today
- 05/31/23
- Nvidia director sells $37.9M in common stock
- 05/31/23
- Nvidia director sells $3.01M in common stock
- 05/15/23
- Berkshire Hathaway takes stake in Capital One, exits RH
- 05/15/23
- Lone Pine boosts Salesforce stake, reduces Visa, Mastercard stakes
- 05/15/23
- Tiger Global buys TSMC, exits AppLovin in Q1
- 04/17/23
- Cadence Design extends collaboration with TSMC, Microsoft
- 05/31/23
- 3M to invest $146M to expand capabilities in biopharma filtration technology
- 05/16/23
- 3M and Svante sign development agreement for carbon dioxide removal products
- 05/15/23
- 3M announces departure of Chief Business and Country Officer Michael Vale
- 05/02/23
- 3M to sell dental local anesthetic portfolio assets to Pierrel for $70M
- 11:50 Today
- GM CEO sees 'huge growth opportunity in Europe'
- 11:36 Today
- GM says every new EV product is more fuel-efficient and more cost-effective
- 11:30 Today
- GM CEO says Tesla has cost advantage in EVs over other car makers
- 11:29 Today
- GM CEO believes EV unit to achieve double digit margins by 2025
- 05/31/23
- Stellantis, Vulcan Energy Resources sign term sheet for new geothermal projects
- 05/25/23
- Stellantis invests in Lyten to accelerate commercialization of 3D Graphene
- 05/25/23
- Stellantis Ventures invests in Lyten
- 05/16/23
- Stellantis to acquire 33.3% stake in Symbio
- 06/01/23
- Dell 'encouraged' over potential for future S&P 500 inclusion
- 06/01/23
- Dell Technologies up 5% after early release of Q1 results
- 06/01/23
- Dell Technologies trading resumes
- 06/01/23
- Dell Technologies reports Q1 cash flow from operations $1.8B
- $811.45 /
+22.87 (+2.90%) - 05/23/23
- Broadcom up 2% after Apple announces 'multibillion-dollar' supply deal
- 05/23/23
- Broadcom reports two separate multi-year statements of work with Apple
- 05/23/23
- Apple reports 'multibillion-dollar' deal with Broadcom for U.S.-made components
- 04/18/23
- Broadcom announces delivery of Jericho3-AI
- 06/01/23
- Congressman Comer probes Federal Trade Commission Chair Khan's 'abuses of power'
- 06/01/23
- EU sets July 6 provisional deadline for review of iRobot, Amazon deal
- 05/31/23
- FTC, DOJ fine Amazon $25M for children's privacy law violations
- 05/30/23
- Amazon Web Services announces general availability of Amazon Security Lake
- 07:35 Today
- 3D Systems confirms submisson of 'superior proposal' for Stratasys combination
- 06/01/23
- Stratasys receives unsolicited takeover proposal from 3D Systems
- 05/30/23
- Nano Dimension to host conference call on special tender offer for Stratasys
- 05/30/23
- Stratasys board unanimously rejects acquisition proposal from Nano Dimension
- 07:35 Today
- 3D Systems confirms submisson of 'superior proposal' for Stratasys combination
- 06/01/23
- Stratasys receives unsolicited takeover proposal from 3D Systems
- 05/25/23
- 3D Systems announced The Technology House has purchased an SLA 750
- 05/09/23
- 3D Systems falls -11.9%
- 06/01/23
- Stratasys receives unsolicited takeover proposal from 3D Systems
- 05/30/23
- Nano Dimension to host conference call on special tender offer for Stratasys
- 05/25/23
- Stratasys to review unsolicited special tender offer from Nano Dimension
- 05/25/23
- Stratasys to combine with Desktop Metal in $1.8B all-stock transaction
- 06/01/23
- JetBlue and Frontier announce divestiture agreement
- 05/25/23
- American Airlines CFO: JetBlue venture 'not meaningful' to outlook
- 05/12/23
- JetBlue announces payment dates for May 2023 prepayment to Spirit stockholders
- 04/25/23
- JetBlue sees summer delays amid air traffic system congestion
- 06/01/23
- JetBlue and Frontier announce divestiture agreement
- 05/31/23
- US Aviation Academy joins Spirit Wings Pilot Pathway program
- 05/12/23
- JetBlue announces payment dates for May 2023 prepayment to Spirit stockholders
- 04/26/23
- Spirit Airlines CFO provides Q2 operational guidance
- 06/01/23
- JetBlue and Frontier announce divestiture agreement
- 05/16/23
- DocuSign names Blake Grayson as incoming CFO
- 05/10/23
- Trade Desk names Laura Schenkein as new CFO
- $337.64 /
+26.05 (+8.36%) - 02/17/23
- Kinsale Capital Group rises 13.1%
- 02/17/23
- Kinsale Capital Group rises 7.0%
- 01/20/23
- Kinsale Capital Group falls -8.3%
- 12/16/22
- Kinsale Capital Group acquires real estate property in Richmond for $76.2M
- 03/29/23
- Warner Music confirms 4% staff headcount cut
- 01/23/23
- Warner Music acquires recorded music rights to English band Yes' catalog
- 12/15/22
- Warner Music announces partnership with DRESSX
- 12/02/22
- Warner Music director Benet sells 15,000 class A common shares
- 12:00 Today
- Samsara rises 28.9%
- 10:00 Today
- Samsara rises 24.6%
- 09:47 Today
- Samsara rises 17.9%
- 05/11/23
- Samsara Chairman Biswas sells $1.7M in company shares
- $33.65 /
+6.535 (+24.10%) - 12:00 Today
- Chemours rises 23.1%
- 11:53 Today
- Pennsylvania AG files complaint against DuPont, affiliates over PFAS
- 10:00 Today
- Chemours rises 18.8%
- 09:47 Today
- Chemours rises 15.3%
- 11:53 Today
- Pennsylvania AG files complaint against DuPont, affiliates over PFAS
- 06:33 Today
- Chemours, DuPont, Corteva reach PFAS settlement with U.S. water systems
- 05/15/23
- Third Point buys Alibaba, cuts AIG in Q1
- 05/02/23
- DuPont to acquire Spectrum Plastics Group from AEA Investors for $1.75B
- 11:53 Today
- Pennsylvania AG files complaint against DuPont, affiliates over PFAS
- 06:33 Today
- Chemours, DuPont, Corteva reach PFAS settlement with U.S. water systems
- 03/28/23
- Pacific Biosciences announces new workflows developed with Corteva
- 03/14/23
- Corteva, Bunge, Chevron team to produce lower carbon winter canola
- 05/16/23
- Zscaler appoints Syam Nair as Chief Technology Officer
- 05/09/23
- Zscaler announces advancements to Zscaler Digital Experience
- 04/24/23
- Zscaler, Rubrik announce new partnership, technology integration
- 04/05/23
- Zscaler down 7% in morning trading
- 05/25/23
- Ginkgo Bioworks, Centrient Pharmaceuticals expand partnership
- 05/11/23
- Cathie Wood's ARK Investment bought 3.7M shares of Ginkgo Bioworks today
- 05/10/23
- Ginkgo Bioworks still expects 2023 revenue at least $275M, consensus $304.03M
- 05/09/23
- Ginkgo Bioworks and Octarine Bio partner to produce natural colors
- 02/22/23
- Xcel Energy raises quarterly dividend by 6.7% to 52c per share
- 01/26/23
- Xcel Energy, Form Energy team to deploy iron-air battery systems
- $365.47 /
+36.525 (+11.10%) - 06/01/23
- Lululemon reports Q1 SSS up 13%
- 06/01/23
- Lululemon jumps 11% after Q1 earnings beat and guidance raise to $365.48
- 03/29/23
- Lululemon CFO Meghan Frank acquires 861 shares of company stock
- 03/28/23
- Lululemon jumps 9% to $348.97 after Q4 results, FY23 guidance beat estimates
- 12:00 Today
- PagerDuty falls -16.4%
- 10:00 Today
- PagerDuty falls -13.7%
- 09:47 Today
- PagerDuty falls -13.7%
- 03/28/23
- PagerDuty introduces first Process Automation solution PagerDuty Operations
- $376.58 /
+82.03 (+27.85%) - 06/01/23
- MongoDB jumps 18% to $346.49 after Q1 results, FY24 guidance beat estimates
- 05/25/23
- MongoDB and Alibaba announce four-year partnership extension
- 03/08/23
- MongoDB sees Q1 Atlas revenue flat to down sequentially
- 03/08/23
- MongoDB falls 10% to $206.50 after Q1, FY24 revenue views miss estimates
- 06/01/23
- Five Below sees Q2 comparable sales up 2%-3%
- 04/13/23
- Five Below director sells $4.38M in common stock
- 04/13/23
- Five Below CEO sells $2.99M in common stock
- 04/06/23
- Five Below director sells $2.06M in common stock
- 09:08 Today BMO Capital
- Dollar General price target lowered to $175 from $230 at BMO Capital
- 08:23 Today Raymond James
- Dollar General price target lowered to $200 from $255 at Raymond James
- 07:41 Today Truist
- Dollar General price target lowered to $166 from $214 at Truist
- 07:07 Today Wells Fargo
- Dollar General price target lowered to $178 from $245 at Wells Fargo
- $13.45 /
-7.285 (-35.13%) - 09:25 Today Scotiabank
- SentinelOne price target lowered to $12 from $14 at Scotiabank
- 08:54 Today Loop Capital
- SentinelOne price target lowered to $20 from $25 at Loop Capital
- 08:41 Today Piper Sandler
- SentinelOne price target lowered to $15 from $18 at Piper Sandler
- 08:25 Today Raymond James
- SentinelOne price target lowered to $20 from $25 at Raymond James
- 05/30/23 BofA
- Spirit AeroSystems price target lowered to $25 from $26 at BofA
- 04/27/23 RBC Capital
- Boeing price target lowered to $220 from $225 at RBC Capital
- 04/27/23 Wells Fargo
- Boeing price target raised to $237 from $230 at Wells Fargo
- 04/19/23 Benchmark
- Spirit AeroSystems upgraded to Buy from Netural at Benchmark
- 06/01/23 RBC Capital
- Exxon Mobil downgraded to Sector Perform from Outperform at RBC Capital
- 05/19/23 Mizuho
- Exxon Mobil price target lowered to $130 from $147 at Mizuho
- 05/18/23 Piper Sandler
- Exxon Mobil price target raised to $145 from $134 at Piper Sandler
- 05/15/23 Jefferies
- Exxon Mobil price target lowered to $140 from $148 at Jefferies
- 06/01/23 RBC Capital
- Chevron upgraded to Outperform from Sector Perform at RBC Capital
- 05/31/23 JPMorgan
- Chevron upgraded to Neutral from Underweight at JPMorgan
- 05/24/23 Mizuho
- Chevron price target raised to $202 from $196 at Mizuho
- 05/24/23 Mizuho
- PDC Energy downgraded to Neutral from Buy at Mizuho
- 05/31/23 BofA
- Nvidia price target raised to $500 from $450 at BofA
- 05/31/23 Citi
- Citi tells investors to 'stay long' Nvidia shares
- 05/30/23 Goldman Sachs
- nVent Electric price target raised to $58 from $55 at Goldman Sachs
- 05/26/23 TD Cowen
- Marvell price target raised to $65 from $50 at TD Cowen
- 06/01/23 Needham
- TSMC price target raised to $118 from $110 at Needham
- 04/26/23 Susquehanna
- Susquehanna iPhone build forecast cut after partner checks
- 04/20/23 Loop Capital
- TSMC price target raised to NT$600 from NT$550 at Loop Capital
- 04/19/23 Needham
- Impinj price target raised to $151 from $138 at Needham
- 04/26/23 RBC Capital
- 3M price target raised to $95 from $89 at RBC Capital
- 04/06/23 Barclays
- 3M price target lowered to $103 from $105 at Barclays
- 03/22/23 Barclays
- 3M price target lowered to $105 from $122 at Barclays
- 02/01/23 BofA
- J&J bankruptcy ruling an 'incremental negative' for 3M, says BofA
- 05/01/23 Morgan Stanley
- Morgan Stanley upgrades 'oversold' General Motors to Overweight
- 05/01/23 Morgan Stanley
- General Motors upgraded to Overweight from Equal Weight at Morgan Stanley
- 04/26/23 Deutsche Bank
- General Motors price target lowered to $35 from $37 at Deutsche Bank
- 04/26/23 RBC Capital
- General Motors price target raised to $48 from $46 at RBC Capital
- 05/10/23 Alliance Global Partners
- McEwen Mining price target raised to $10.75 from $9.50 at Alliance Global Partners
- 03/06/23 Berenberg
- Stellantis price target raised to EUR 21 from EUR 18 at Berenberg
- 03/03/23 RBC Capital
- Stellantis upgraded to Outperform from Sector Perform at RBC Capital
- 02/24/23 RBC Capital
- Stellantis price target raised to EUR 19 from EUR 18 at RBC Capital
- 11:19 Today Evercore ISI
- Dell Technologies removed from 'Tactical Outperform' list at Evercore ISI
- 08:22 Today Raymond James
- Dell Technologies price target raised to $50 from $45 at Raymond James
- 07:54 Today Deutsche Bank
- Dell Technologies price target raised to $48 from $45 at Deutsche Bank
- 07:39 Today Morgan Stanley
- Dell Technologies price target raised to $56 from $55 at Morgan Stanley
- $811.45 /
+22.87 (+2.90%) - 09:23 Today Truist
- Broadcom price target raised to $890 from $700 at Truist
- 08:44 Today Piper Sandler
- Broadcom price target raised to $830 from $715 at Piper Sandler
- 08:22 Today Evercore ISI
- Broadcom price target raised to $875 from $850 at Evercore ISI
- 07:54 Today Deutsche Bank
- Broadcom price target raised to $870 from $675 at Deutsche Bank
- 11:38 Today JPMorgan
- JPMorgan 'most comfortable defending' T-Mobile after Amazon wireless headlines
- 08:57 Today Piper Sandler
- Pinterest, Amazon partnership should be 'win-win,' says Piper Sandler
- 06/01/23 Stifel
- Veritone price target lowered to $4 from $5 at Stifel
- 06/01/23 Roth MKM
- Veritone downgraded to Neutral from Buy at Roth MKM
- 05/26/23 William Blair
- Stratasys acquisition of Desktop could be a mistake, says William Blair
- 05/25/23 Lake Street
- Stratasys deal 'appears to be total desperation move,' says Lake Street
- 05/17/23 Lake Street
- Stratasys price target trimmed to $21 at Lake Street after 'solid quarter'
- 03/10/23 Lake Street
- Nano Dimension made 'lowball offer' Stratasys won't accept, says Lake Street
- 08/16/22 Credit Suisse
- 3D Systems initiated with an Underperform at Credit Suisse
- 05/26/23 William Blair
- Stratasys acquisition of Desktop could be a mistake, says William Blair
- 05/25/23 Lake Street
- Stratasys deal 'appears to be total desperation move,' says Lake Street
- 03/02/23 Craig-Hallum
- Craig-Hallum 'warming to' Desktop Metal after new supply agreement
- 01/06/23 Morgan Stanley
- Desktop Metal initiated with an Equal Weight at Morgan Stanley
- 05/08/23 JPMorgan
- JetBlue price target lowered to $8 from $10 at JPMorgan
- 03/15/23 TD Cowen
- JetBlue price target lowered to $8 from $9 at TD Cowen
- 01/27/23 Wolfe Research
- JetBlue price target raised to $7 from $6 at Wolfe Research
- 12/20/22 Deutsche Bank
- JetBlue price target lowered to $8.50 from $10 at Deutsche Bank
- 05/08/23 JPMorgan
- Spirit Airlines price target lowered to $10 from $28 at JPMorgan
- 03/15/23 TD Cowen
- Spirit Airlines price target lowered to $20 from $30 at TD Cowen
- 12/20/22 Deutsche Bank
- Spirit Airlines downgraded on regulatory process at Deutsche Bank
- 12/20/22 Deutsche Bank
- Spirit Airlines downgraded to Hold from Buy at Deutsche Bank
- 05/08/23 JPMorgan
- Frontier Group downgraded to Neutral from Overweight at JPMorgan
- 05/04/23 TD Cowen
- Frontier Group price target lowered to $16 from $19 at TD Cowen
- 05/04/23 Susquehanna
- Frontier Group downgraded on elevated growth risk at Susquehanna
- 05/04/23 Susquehanna
- Frontier Group downgraded to Neutral from Positive at Susquehanna
- 06/01/23 Morgan Stanley
- Morgan Stanley upgrades 'ad tech's best-in-class' Trade Desk to Overweight
- 06/01/23 Morgan Stanley
- Trade Desk upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/01/23 RBC Capital
- Trade Desk price target raised to $85 from $77 at RBC Capital
- 05/24/23 Citi
- Trade Desk growth supported by connected TV 'inflection,' says Citi
- $337.64 /
+26.05 (+8.36%) - 05:14 Today BMO Capital
- Kinsale Capital upgraded to Outperform from Underperform at BMO Capital
- 04/10/23 Jefferies
- Kinsale Capital Group price target raised to $315 from $313 at Jefferies
- 04/05/23 BMO Capital
- Kinsale Capital Group price target raised to $245 from $230 at BMO Capital
- 02/21/23 Truist
- Kinsale Capital Group price target raised to $400 from $335 at Truist
- 04:51 Today Atlantic Equities
- Warner Music downgraded to Neutral from Overweight at Atlantic Equities
- 05/12/23 Barclays
- Warner Music price target lowered to $30 from $34 at Barclays
- 04/25/23 JPMorgan
- Warner Music price target lowered to $40 from $42 at JPMorgan
- 04/21/23 Morgan Stanley
- Warner Music price target lowered to $38 from $41 at Morgan Stanley
- 09:28 Today BMO Capital
- Samsara price target raised to $23 from $19 at BMO Capital
- 08:51 Today Piper Sandler
- Samsara price target raised to $23 from $21 at Piper Sandler
- 07:52 Today TD Cowen
- Samsara price target raised to $26 from $23 at TD Cowen
- 07:18 Today Wells Fargo
- Samsara price target raised to $25 from $23 at Wells Fargo
- $33.65 /
+6.535 (+24.10%) - 15:03 Today Deutsche Bank
- PFAS settlement a 'major positive' for DuPont, says Deutsche Bank
- 05/01/23 RBC Capital
- Chemours price target raised to $36 from $35 at RBC Capital
- 04/28/23 Credit Suisse
- Chemours price target lowered to $25 from $27 at Credit Suisse
- 02/13/23 RBC Capital
- Chemours price target raised to $36 from $33 at RBC Capital
- 15:03 Today Deutsche Bank
- PFAS settlement a 'major positive' for DuPont, says Deutsche Bank
- 05/15/23 Deutsche Bank
- DuPont upgraded to Buy from Hold at Deutsche Bank
- 05/04/23 RBC Capital
- DuPont price target lowered to $81 from $92 at RBC Capital
- 05/03/23 Deutsche Bank
- DuPont price target lowered to $70 from $82 at Deutsche Bank
- 15:03 Today Deutsche Bank
- PFAS settlement a 'major positive' for DuPont, says Deutsche Bank
- 06/01/23 Barclays
- Corteva price target lowered to $70 from $75 at Barclays
- 05/22/23 Vertical Research
- Corteva upgraded to Buy from Hold at Vertical Research
- 05/08/23 Deutsche Bank
- Corteva price target lowered to $68 from $75 at Deutsche Bank
- 09:26 Today Scotiabank
- Zscaler price target raised to $150 from $138 at Scotiabank
- 09:10 Today BMO Capital
- Zscaler price target raised to $150 from $120 at BMO Capital
- 09:06 Today Stifel
- Zscaler price target raised to $150 from $135 at Stifel
- 08:51 Today Loop Capital
- Zscaler price target raised to $135 from $125 at Loop Capital
- 04:40 Today Goldman Sachs
- Ginkgo Bioworks downgraded to Sell from Neutral at Goldman Sachs
- 05/11/23 William Blair
- Ginkgo downgraded on guidance concerns at William Blair
- 05/11/23 William Blair
- Ginkgo Bioworks downgraded to Market Perform from Outperform at William Blair
- 03/05/23 BTIG
- Ginkgo Bioworks price target lowered to $3 from $4 at BTIG
- 05:00 Today JPMorgan
- Xcel Energy downgraded to Neutral from Overweight at JPMorgan
- 04:55 Today Wolfe Research
- Xcel Energy downgraded to Peer Perform from Outperform at Wolfe Research
- 05/30/23 Mizuho
- Xcel Energy price target lowered to $69 from $72 at Mizuho
- 04/05/23 BMO Capital
- Xcel Energy price target lowered to $73 from $74 at BMO Capital
- $365.47 /
+36.525 (+11.10%) - 09:26 Today BMO Capital
- Lululemon price target raised to $355 from $340 at BMO Capital
- 08:48 Today Piper Sandler
- Lululemon price target raised to $445 from $390 at Piper Sandler
- 07:45 Today Morgan Stanley
- Lululemon price target raised to $424 from $405 at Morgan Stanley
- 07:45 Today TD Cowen
- Lululemon price target raised to $531 from $525 at TD Cowen
- 09:01 Today Craig-Hallum
- Craig-Hallum downgrades PagerDuty on 'rocky start' to 2023
- 07:54 Today TD Cowen
- PagerDuty price target lowered to $29 from $35 at TD Cowen
- 07:45 Today RBC Capital
- PagerDuty price target lowered to $32 from $37 at RBC Capital
- 07:42 Today Canaccord
- PagerDuty price target lowered to $30 from $33 at Canaccord
- $376.58 /
+82.03 (+27.85%) - 09:02 Today RBC Capital
- MongoDB price target raised to $400 from $235 at RBC Capital
- 07:59 Today Stifel
- MongoDB price target raised to $375 from $240 at Stifel
- 07:21 Today Truist
- MongoDB price target raised to $365 from $235 at Truist
- 07:19 Today Needham
- MongoDB price target raised to $430 from $250 at Needham
- 09:03 Today Craig-Hallum
- Five Below price target lowered to $224 from $235 at Craig-Hallum
- 08:27 Today Roth MKM
- Five Below price target lowered to $225 from $240 at Roth MKM
- 07:56 Today Deutsche Bank
- Five Below price target raised to $239 from $238 at Deutsche Bank
- 07:30 Today Truist
- Five Below price target lowered to $222 from $224 at Truist
- 06/01/23
- Dollar General reports Q1 EPS $2.34, consensus $2.38
- 05/31/23
- Notable companies reporting before tomorrow's open
- 05/31/23
- Notable companies reporting before tomorrow's open
- 03/16/23
- Dollar General sees FY23 EPS growth 4%-6%, consensus $11.43
- $13.45 /
-7.285 (-35.13%) - 06/01/23
- SentinelOne cuts FY24 revenue view to $590M-$600M from $631M-$640M
- 06/01/23
- SentinelOne sees Q2 revenue $141M, consensus $151.92M
- 06/01/23
- SentinelOne reports Q1 adjusted EPS (15c), consensus (17c)
- 06/01/23
- Notable companies reporting after market close
- 05/03/23
- Spirit AeroSystems reports Q1 EPS ($1.69), consensus (29c)
- 04/26/23
- Boeing sees Q2 core EPS roughly in line with 1Q23 absent tanker charge
- 04/26/23
- Boeing reports Q1 core EPS ($1.27), consensus ($1.07)
- 04/25/23
- Notable companies reporting before tomorrow's open
- 04/28/23
- Exxon Mobil reports Q1 adjusted EPS $2.83, consensus $2.59
- 04/27/23
- Notable companies reporting before tomorrow's open
- 04/27/23
- Notable companies reporting before tomorrow's open
- 01/31/23
- Exxon Mobil reports Q4 adjusted EPS $3.40, consensus $3.29
- 04/28/23
- Chevron reports Q1 adjusted EPS $3.55, consensus $3.41
- 04/27/23
- Notable companies reporting before tomorrow's open
- 04/27/23
- Notable companies reporting before tomorrow's open
- 01/27/23
- Chevron reports Q4 adjusted EPS $4.09, consensus $4.38
- 05/24/23
- Nvidia jumps 15% to $350.53 after Q1 beat, better than expected guidance
- 05/24/23
- Nvidia sees Q2 revenue $11B +/- 2%, consensus 7.15B
- 05/24/23
- Nvidia sees Q2 revenue $11B, +/- 2%, consensus $7.15B
- 05/24/23
- Nvidia reports Q1 EPS $1.09, consensus 92c
- 04/20/23
- TSMC sees Q2 revenue $15.2B-$16B, consensus $15.98B
- 04/20/23
- TSMC reports Q1 EPS $1.31, consensus $1.20
- 01/12/23
- TSMC sees Q1 revenue $16.7B-$17.5B, consensus $17.71B
- 01/12/23
- TSMC reports Q4 EPS $1.82, consensus $1.77
- 04/25/23
- 3M backs FY23 adjusted EPS view $8.50-$9.00, consensus $8.60
- 04/25/23
- 3M reports Q1 adjusted EPS $1.97, consensus $1.58
- 04/24/23
- Notable companies reporting before tomorrow's open
- 04/24/23
- Notable companies reporting before tomorrow's open
- 04/25/23
- General Motors raises FY23 adjusted EPS view to $6.35-$7.35 from $6.00-$7.00
- 04/25/23
- General Motors reports Q1 adjusted EPS $2.21, consensus $1.71
- 04/24/23
- Notable companies reporting before tomorrow's open
- 04/24/23
- Notable companies reporting before tomorrow's open
- 05/03/23
- Stellantis reports Q1 revenue EUR 47.24B vs. EUR 47.2B last year
- 06/01/23
- Dell Technologies reports Q1 adjusted EPS $1.31, consensus 86c
- 06/01/23
- Notable companies reporting after market close
- 03/02/23
- Dell Technologies reports Q4 adjusted EPS $1.80, consensus $1.63
- 03/02/23
- Notable companies reporting after market close
- $811.45 /
+22.87 (+2.90%) - 06/01/23
- Broadcom sees Q3 revenue approximately $8.85B, consensus $8.72B
- 06/01/23
- Broadcom reports Q2 adjusted EPS $10.32, consensus $10.08
- 06/01/23
- Notable companies reporting after market close
- 03/02/23
- Broadcom sees Q2 revenue approximately $8.7B, consensus $8.59B
- 04/27/23
- Amazon sees Q2 revenue $127B-$133B, consensus $129.83B
- 04/27/23
- Amazon reports Q1 EPS 31c with Rivian loss, consensus 21c
- 04/27/23
- Notable companies reporting after market close
- 02/02/23
- Amazon sees Q1 revenue $121B-$126B, consensus $125.11B
- 05/25/23
- Stratasys backs FY23 EPS view 12c-24, consensus 17c
- 05/16/23
- Stratasys sees FY23 EPS 12c-24c, consensus 16c
- 05/16/23
- Stratasys reports Q1 EPS 2c, consensus (6c)
- 03/02/23
- Stratasys sees FY23 EPS 12c-24c, consensus 20c
- 05/08/23
- 3D Systems backs FY23 revenue view $545M-$575M, consensus $557.07M
- 05/08/23
- 3D Systems reports Q1 EPS (9c), consensus (7c)
- 02/28/23
- 3D Systems sees positive FY23 adjusted EBITDA
- 02/28/23
- 3D Systems reports Q4 EPS (6c), consensus (8c)
- 05/25/23
- Desktop Metal backs FY23 revenue view $210M-$260M, consensus $218.4M
- 05/10/23
- Desktop Metal affirms 2023 revenue outlook $210M-$260M, consensus $237.52M
- 05/10/23
- Desktop Metal reports Q1 EPS (16c), consensus (8c)
- 03/01/23
- Desktop Metal sees FY23 revenue $210M-$260M, consensus $259.87M
- 04/25/23
- JetBlue reaffirms FY23 EPS view 70c-$1.00, consensus 52c
- 04/25/23
- JetBlue CFO sees margins near 'pre-pandemic levels later in year'
- 04/25/23
- JetBlue sees Q2 revenue up 4.5% - 8.5% YoY
- 04/25/23
- JetBlue backs Q2 EPS 35c-45c, consensus 30c
- 04/26/23
- Spirit Airlines reports Q1 adjusted EPS (82c), consensus (85c)
- 04/26/23
- Notable companies reporting after market close
- 04/25/23
- JetBlue reaffirms FY23 EPS view 70c-$1.00, consensus 52c
- 02/06/23
- Spirit Airlines reports Q4 adjusted EPS 12c, consensus 4c
- 05/03/23
- Frontier Group reports Q1 EPS (6c), consensus (8c)
- 02/08/23
- Frontier Group sees Q1 adjusted pre-tax margin between (6%)-(2%)
- 02/08/23
- Frontier Group reports Q4 EPS 18c, consensus 17c
- 05/10/23
- Trade Desk sees Q2 revenue 'at least' $452M, consensus $445.4M
- 05/10/23
- Trade Desk reports Q1 EPS 23c, consensus 12c
- 05/10/23
- Notable companies reporting after market close
- 02/15/23
- Trade Desk sees Q1 revenue at least $363M, consensus $360.94M
- $337.64 /
+26.05 (+8.36%) - 04/27/23
- Kinsale Capital Group reports Q1 EPS $2.40, consensus $2.21
- 02/16/23
- Kinsale Capital Group reports Q4 adjusted EPS $2.60, consensus $2.15
- 05/09/23
- Warner Music reports Q2 EPS 6c, consensus 18c
- 02/09/23
- Warner Music reports Q1 EPS 23c, consensus 26c
- 06/01/23
- Samsara raises FY24 EPS view to (2c)-0c from (7c)-(5c), consensus (7c)
- 06/01/23
- Samsara sees Q2 adjusted EPS (3c)-(2c), consensus (3c)
- 06/01/23
- Samsara reports Q1 adjusted EPS (2c), consensus (5c)
- 06/01/23
- Notable companies reporting after market close
- $33.65 /
+6.535 (+24.10%) - 04/27/23
- Chemours reports Q1 adjusted EPS 98c, consensus 47c
- 02/09/23
- Chemours sees FY23 EPS $3.80-$4.29, consensus $4.09
- 02/09/23
- Chemours reports Q4 EPS 0c, consensus 8c
- 05/02/23
- DuPont narrows FY23 adjusted EPS view to $3.55-$3.70 from $3.50-$4.00
- 05/02/23
- DuPont sees Q2 EPS 84c, consensus $1.10
- 05/02/23
- DuPont reports Q1 adjusted EPS 84c, consensus $1.13
- 02/07/23
- DuPont sees FY23 adjusted EPS $3.50-$4.00, consensus $3.84
- 05/03/23
- Corteva raises FY23 operating EPS view to $2.80-$3.00 from $2.70-$2.90
- 05/03/23
- Corteva reports Q1 adjusted EPS $1.16, consensus 93c
- 02/01/23
- Corteva sees FY23 operating EPS $2.70-$2.90, consensus $3.13
- 02/01/23
- Corteva reports Q4 adjusted EPS 16c, consensus 5c
- 06/01/23
- Zscaler sees FY23 EPS $1.63-$1.64, consensus $1.55
- 06/01/23
- Zscaler sees Q4 EPS approximately 49c, consensus 47c
- 06/01/23
- Zscaler reports Q3 EPS 48c, consensus 42c
- 06/01/23
- Notable companies reporting after market close
- 05/10/23
- Ginkgo Bioworks reports Q1 EPS (11c), consensus (9c)
- 03/01/23
- Ginkgo Bioworks sees 2023 revenue at least $275M, consensus $381.51M
- 03/01/23
- Ginkgo Bioworks reports Q4 EPS (10c), consensus (21c)
- 01/11/23
- Ginkgo Bioworks backs FY22 revenue view $460M-$480M, consensus $470.79M
- 05/19/23
- Xcel Energy backs FY23 EPS guidance of $3.30-$3.40, consensus $3.38
- 04/27/23
- Xcel Energy backs FY23 EPS view $3.30-$3.40, consensus $3.38
- 04/27/23
- Xcel Energy reports Q1 EPS 76c, consensus 74c
- 04/05/23
- Xcel Energy affirms FY23 EPS $3.30-$3.40, updates on MN rate case
- $365.47 /
+36.525 (+11.10%) - 06/01/23
- Lululemon sees FY23 EPS $11.74-$11.94, consensus $11.61
- 06/01/23
- Lululemon sees Q2 EPS $2.47-$2.52 , consensus $2.50
- 06/01/23
- Lululemon reports Q1 EPS $2.28, consensus $1.98
- 06/01/23
- Notable companies reporting after market close
- 06/01/23
- PagerDuty raises FY24 adjusted EPS view to 60c-65c from 45c-50c
- 06/01/23
- PagerDuty sees Q2 adjusted EPS 10c-11c, consensus 9c
- 06/01/23
- PagerDuty reports Q1 adjusted EPS 20c, consensus 9c
- 03/15/23
- PagerDuty sees FY24 adjusted EPS 45c-50c, consensus 20c
- $376.58 /
+82.03 (+27.85%) - 06/01/23
- MongoDB sees FY24 non-GAAP EPS $1.42-$1.56, consensus $1.03
- 06/01/23
- MongoDB sees Q2 non-GAAP EPS 43c-46c, consensus 14c
- 06/01/23
- MongoDB reports Q1 non-GAAP EPS 56c, consensus 19c
- 06/01/23
- Notable companies reporting after market close
- 06/01/23
- Five Below narrows FY23 EPS view to $5.31-$5.71 from $5.25-$5.76
- 06/01/23
- Five Below sees Q2 EPS 80c-85c, consensus 88c
- 06/01/23
- Five Below reports Q1 EPS 67c, consensus 63c
- 06/01/23
- Notable companies reporting after market close
|
|
Conference/Events
| ShowHide Related Items >><< - 05/31/23
- Ascendis Pharma announces oncology program update
- 05/01/23
- Ascendis Pharma receives FDA CRL for TransCon PTH in hypoparathyroidism
- 04/03/23
- Ascendis Pharma falls 38% after disclosing FDA notice of deficiencies in NDA
- 04/03/23
- Ascendis' Phase 1/2 initial trial results of TransCon accepted for ASCO 2023
- 05/18/23
- Zymeworks president, COO Neil Klompas departs
- 03/30/23
- Zymeworks discloses $1.6M purchase of common stock by Ecor1 Capital
- 01/23/23
- Zymeworks shareholder EcoR1 Capital buys $3.0M in company shares
- 01/19/23
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA
BCYC Bicycle Therapeutics - 05/11/23
- Bicycle Therapeutics and Orano Med report radio-conjugate data results
- 05/10/23
- Bicycle Therapeutics jumps 8% after Bayer oncology pact, milestone payment
- 05/10/23
- Bicycle to receive $45M upfront, plus future milestones in Bayer oncology pact
- 04/03/23
- Bicycle Therapeutics names Santiago Arroyo, M.D Chief Development Officer
IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
- 04/17/23
- Kura reports preclinical data on use of farnesyl transferase inhibitors
- 02/09/23
- Kura Oncology announces first patients dosed in Phase 2 trial of ziftomenib
- 01/24/23
- Kura Oncology jumps 6% to $14.85 as FDA clears its IND application for KO-2806
- 01/24/23
- Kura Oncology announces FDA clearance of IND application for KO-2806
- 06/01/23
- Pfizer announces results from Phase 3 program of REVISIT, ASSEMBLE studies
- 05/31/23
- Pfizer says FDA approves RSV prevention vaccine
- 05/30/23
- Seagen shareholders approve acquisition by Pfizer
- 05/30/23
- Pfizer's marstacimab shows significant efficacy in Phase 3 hemophilia trial
- 05/05/23
- Arvinas expects cash to fund requirements into 2026
- 04/03/23
- Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader
- 02/23/23
- Arvinas expects cash to fund requirements into 2026
- 12/16/22
- Arvinas appoints Everett Cunningham to board of directors
- 05/17/23
- Genentech announces fenebrutinib study met primary, secondary endpoint
- 05/09/23
- Genentech announces FDA acceptance of Vabysmo sBLA
- 04/26/23
- Roche reports CHMP recommends EU approval of fixed-duration Columvi
- 04/26/23
- Zentalis enters agreements with Foundation Medicine, Roche
- 05/31/23
- Sanofi announces new data on frexalimab, to present at 2023 CMSC
- 05/21/23
- Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results
- 05/18/23
- Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims
- 05/18/23
- Supreme Court upholds Sanofi PCSK9 drug patent victory over Amgen
- 15:57 Today
- AstraZeneca's IMFINZI plus chemo improved pathologic response in Phase III trial
- 12:06 Today
- AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial
- 06/01/23
- AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer
- 06/01/23
- Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA
- $441.99 /
+5.515 (+1.26%) - 05/26/23
- Attorneys announce over $500M pact with Eli Lilly to settle class-action suit
- 05/23/23
- Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare
- 05/18/23
- Eli Lilly announces detailed results from peresolimab study published in NEJM
- 05/03/23
- Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target
- 05/11/23
- ALX Oncology expects cash to fund operations through mid-2025
- 05/09/23
- ALX Oncology announces first patient dosed in Phase 2 trial of evorpacept
- 04/25/23
- ALX Oncology enters clinical trial collaboration with Sanofi
- 03/13/23
- ALX Oncology, Quantum Leap dose first patient in I-SPY-P1 trial
- 07:56 Today Wedbush
- Ascendis Pharma price target raised to $187 from $186 at Wedbush
- 05/08/23 Wedbush
- Ascendis Pharma added to Best Ideas List at Wedbush
- 04/28/23 Cantor Fitzgerald
- Ascendis Pharma price target raised to $152 from $142 at Cantor Fitzgerald
- 04/12/23 Morgan Stanley
- Ascendis Pharma price target lowered to $107 from $108 at Morgan Stanley
- 05/18/23 Citi
- Zymeworks price target raised to $18 from $17 at Citi
- 05/09/23 Stifel
- Zymeworks price target raised to $19 from $18 at Stifel
- 03/20/23 Wells Fargo
- Zymeworks coverage transferred at Wells Fargo with Overweight rating
- 03/10/23 Citi
- Zymeworks price target lowered to $17 from $21 at Citi
BCYC Bicycle Therapeutics - 01/04/23 EF Hutton
- Bicycle Therapeutics initiated with a Buy at EF Hutton
- 01/02/23 Barclays
- Barclays views GSK acquisition interest as positive for oncology stocks
- 11/10/22 Piper Sandler
- Bicycle Therapeutics price target raised to $48 from $37 at Piper Sandler
- 11/09/22 JMP Securities
- Bicycle Therapeutics price target lowered to $46 from $70 at JMP Securities
IOVA Iovance Biotherapeutics - 05/30/23 Wells Fargo
- Iovance upgraded to Overweight at Wells Fargo after lifileucel BLA accepted
- 05/30/23 Wells Fargo
- Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- 05/30/23 Stifel
- Iovance Biotherapeutics price target raised to $24 from $21 at Stifel
- 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/31/23 Barclays
- Barclays reveals two small cap ideas into ASCO conference
- 05/16/23 BTIG
- Kura Oncology initiated with a Buy at BTIG
- 05/11/23 Stifel
- Kura Oncology price target lowered to $24 from $25 at Stifel
- 04/17/23 H.C. Wainwright
- Kura Oncology data support KO-2806 combination studies, says H.C. Wainwright
- 05/23/23 Jefferies
- Jefferies says Pfizer oral GLP-1 safety and tolerability 'important to note'
- 05/22/23
- Pfizer weight loss drug may be as effective, quicker than Ozempic, CNBC says
- 05/19/23 BofA
- AdComm support for Pfizer's infant RSV vaccine 'not surprising,' says BofA
- 05/16/23 Stifel
- Seagen likely to stay 'distanced' from deal price after FTC action, says Stifel
- 05/08/23 Stifel
- Arvinas price target lowered to $72 from $75 at Stifel
- 03/18/23 Citi
- Arvinas price target raised to $77 from $72 at Citi
- 02/23/23 Capital One
- Arvinas remains one of the best biotechs to own, says Capital One
- 01/17/23 Truist
- Arvinas price target lowered to $65 from $100 at Truist
- 05/19/23 Piper Sandler
- Regeneron Q1 Eylea miss 'not about share, says Piper Sandler
- 05/08/23 Guggenheim
- Regeneron price target lowered to $935 from $960 at Guggenheim
- 04/10/23 BofA
- BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
- 03/27/23 Barclays
- Roche downgraded to Equal Weight from Overweight at Barclays
- 05/19/23 BofA
- AdComm support for Pfizer's infant RSV vaccine 'not surprising,' says BofA
- 05/04/23 Raymond James
- Kymera Therapeutics upgraded to Outperform from Market Perform at Raymond James
- 04/28/23 Deutsche Bank
- Sanofi downgraded to Sell from Hold at Deutsche Bank
- 04/28/23 Deutsche Bank
- Sanofi downgraded to Sell from Hold at Deutsche Bank
- 05/26/23 Argus
- AstraZeneca price target lowered to $80 from $85 at Argus
- 05/09/23 Berenberg
- AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
- 04/28/23 JPMorgan
- AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
- 04/13/23 Argus
- AstraZeneca price target raised to $85 from $75 at Argus
- $441.99 /
+5.515 (+1.26%) - 05/26/23 Wells Fargo
- Eli Lilly price target raised to $500 from $440 at Wells Fargo
- 05/24/23 BofA
- Eli Lilly price target raised to $500 from $450 at BofA
- 05/23/23 TD Cowen
- Eli Lilly price target raised to $500 from $430 at TD Cowen
- 05/19/23 JPMorgan
- JPMorgan places 'Negative Catalyst Watch' on Novartis into data
- 03/14/23 UBS
- ALX Oncology price target lowered to $29 from $31 at UBS
- 03/10/23 H.C. Wainwright
- ALX Oncology price target lowered to $30 from $65 at H.C. Wainwright
- 11/09/22 Cantor Fitzgerald
- ALX Oncology price target lowered to $22 from $32 at Cantor Fitzgerald
- 11/09/22 H.C. Wainwright
- ALX Oncology price target lowered to $65 from $80 at H.C. Wainwright
- 12/01/22 H.C. Wainwright
- Portage Biotech price target lowered to $21 from $22 at H.C. Wainwright
- 11/30/22 Cantor Fitzgerald
- Portage Biotech price target lowered to $18 from $26 at Cantor Fitzgerald
- 11/30/22 Oppenheimer
- Portage Biotech price target lowered to $18 from $26 at Oppenheimer
- 09/20/22 H.C. Wainwright
- Portage Biotech price target lowered to $22 from $32 at H.C. Wainwright
- 05/08/23
- Zymeworks reports Q1 adjusted EPS (34c), consensus (54c)
- 03/07/23
- Zymeworks reports Q4 EPS $4.65, consensus $4.84
BCYC Bicycle Therapeutics - 05/04/23
- Bicycle Therapeutics reports Q1 EPS ($1.30), consensus ($1.07)
- 02/28/23
- Bicycle Therapeutics reports Q4 EPS ($1.01), consensus ($1.06)
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
- 02/23/23
- Kura Oncology reports Q4 EPS (49c), consensus (57c)
- 05/02/23
- Pfizer backs FY23 adjusted EPS view $3.25-$3.45, consensus $3.36
- 05/02/23
- Pfizer reports Q1 adjusted EPS $1.23, consensus 98c
- 03/15/23
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
- 01/31/23
- Pfizer sees FY23 adjusted EPS $3.25-$3.45, consensus $4.44
- 05/05/23
- Arvinas reports Q1 EPS ($1.54), consensus ($1.51)
- 02/23/23
- Arvinas reports Q4 EPS ($1.56), consensus ($1.22)
- 04/26/23
- Roche confirms outlook for FY23
- 04/26/23
- Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year
- 02/02/23
- Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year
- 04/27/23
- Sanofi confirms FY23 business EPS view of up low single digits at CER
- 04/27/23
- Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER
- 03/30/23
- IGM Biosciences Sanofi sees FY23 revenue $3M, consensus $5.5M
- 02/03/23
- Sanofi sees 2023 business EPS up at low single digit rate at CER
- 04/27/23
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
- 04/27/23
- AstraZeneca reports Q1 core EPS $1.92, consensus $1.07
- 02/09/23
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
- 02/09/23
- AstraZeneca reports Q4 core EPS $1.38, consensus $1.35
- $441.99 /
+5.515 (+1.26%) - 04/27/23
- Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55
- 04/27/23
- Eli Lilly reports Q1 EPS $1.62, consensus $1.73
- 04/26/23
- Notable companies reporting before tomorrow's open
- 04/26/23
- Notable companies reporting before tomorrow's open
- 05/11/23
- ALX Oncology reports Q1 EPS (74c), consensus (80c)
- 03/01/23
- Portage Biotech reports Q4 EPS (44c), consensus (23c)
- 05/26/23
- Health authorities to target next COVID shot to new strain, WSJ says
- 05/23/23
- China's new Covid surge could result in 65M infections a week, Bloomberg says
- 05/14/23
- Pfizer Pfizer, Stryker have strong growth prospects, Barron's says
- 05/10/23
- BioNTech pancreatic cancer vaccine 'shows promise' in small trial, NYT says
- 05/10/23
- BioNTech data was reported in June 2022, Reuters reports
- 01/11/23
- Roche looks internally for pharmaceutical unit chief, Bloomberg reports
- 04/12/23
- Sanders to call CEOs of largest insulin makers to testify, STAT says
- 01/30/23
- Sanofi plans to lay off staff at vaccine factories in India, Reuters says
- 01/23/23
- CytoReason to license IBD disease model to Sanofi
- 01/13/23
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- 05/26/23
- Health authorities to target next COVID shot to new strain, WSJ says
- 05/19/23
- Astra China head says company seeks to 'love the Communist Party,' Reuters says
- 05/04/23
- AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports
- 04/06/23
- GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says
- $441.99 /
+5.515 (+1.26%) - 04/24/23
- Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report
- 04/12/23
- Sanders to call CEOs of largest insulin makers to testify, STAT says
- 04/11/23
- Drugmakers call for abortion pill ruling reversal, Reuters reports
- 04/10/23
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- 05/04/23
- Biotech Alert: Searches spiking for these stocks today
- 05/03/23
- Biotech Alert: Searches spiking for these stocks today
- 04/06/23
- Biotech Alert: Searches spiking for these stocks today
- 04/05/23
- Biotech Alert: Searches spiking for these stocks today
- 03/08/23
- Fly Intel: Pre-market Movers
- 01/12/23
- Fly Intel: After-Hours Movers
- 12/19/22
- What You Missed On Wall Street On Monday
- 12/19/22
- What You Missed On Wall Street This Morning
IOVA Iovance Biotherapeutics - 11:00 Today
- Biotech Alert: Searches spiking for these stocks today
- 06/01/23
- Biotech Alert: Searches spiking for these stocks today
- 05/30/23
- What You Missed On Wall Street On Tuesday
- 05/30/23
- What You Missed On Wall Street This Morning
- 05/17/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/21/23
- Biotech Alert: Searches spiking for these stocks today
- 05/16/23
- What You Missed On Wall Street On Tuesday
- 05/02/23
- What You Missed On Wall Street On Tuesday
- 05/02/23
- What You Missed On Wall Street This Morning
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 01/23/23
- Biotech Alert: Searches spiking for these stocks today
- 01/12/23
- Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover
- 05/10/23
- What Wall Street is saying about Disney ahead of earnings
- 03/23/23
- What You Missed On Wall Street On Thursday
- 03/23/23
- What You Missed On Wall Street This Morning
- 03/14/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/11/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 04/05/23
- What You Missed On Wall Street On Wednesday
- 04/05/23
- What You Missed On Wall Street This Morning
- 02/09/23
- What You Missed On Wall Street This Morning
- $441.99 /
+5.515 (+1.26%) - 05/03/23
- What You Missed On Wall Street On Wednesday
- 05/03/23
- What You Missed On Wall Street This Morning
- 05/03/23
- Fly Intel: Pre-market Movers
- 04/27/23
- What You Missed On Wall Street On Thursday
- 05/24/23
- Notable open interest changes for May 24th
- 05/23/23
- Unusually active option classes on open May 23rd
- 05/23/23
- Notable open interest changes for May 23rd
- 05/23/23
- Unusual call flow in option market yesterday
- 05/26/23
- Unusually active option classes on open May 26th
- 05/18/23
- Unusually active option classes on open May 18th
- 05/09/23
- AstraZeneca put volume heavy and directionally bearish
- 04/27/23
- Unusually active option classes on open April 27th
- $441.99 /
+5.515 (+1.26%) - 03/13/23
- Early notable gainers among liquid option names on March 13th
- 03/10/23
- Early notable gainers among liquid option names on March 10th
|
